ClinicaliQ Trial Snapshot
- Secondary Care Colorectal Cancer Pathway Review — Recruiting • Oncology • NCT07430527.
- What is being tested: A secondary care colorectal cancer pathway review examining systems and processes for detecting, diagnosing, and managing bowel cancer in hospital settings to identify improvements in early detection and patient outcomes.
- Patient eligibility overview: The review focuses on patients with suspected or confirmed colorectal cancer presenting through secondary care pathways in Scotland, encompassing the diagnostic and treatment journey from referral through hospital services.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
Bowel cancer (colorectal cancer) is the 4th most common cancer in Scotland. Approximately 4,000 cases are diagnosed annually. Cancer-related deaths in Scotland are higher than other UK nations. Improving the early detection of bowel cancer, and therefore survival, is important. The majority of bowel cancers are diagnosed within secondary-care (colorectal surgery unit). Upon GP referral to secondary-care, patients provide stool samples which are analysed for microscopic blood (FIT; faecal immunohistochemical test). Patients with a single positive result are more likely to have bowel cancer (0.2% risk if no blood detected,…
Eligibility Snapshot
- : Patients managed within the NHS Lothian CRC USoC/urgent pathway (including urgent referrals) due to 'red-flag' symptoms concerning of CRC from April 2022 to August 2025.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.